Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug

Context Therapeutics

02/04/2026 12:43

** Shares of Context Therapeutics CNTX.O rise 9% to $2.89 premarket

** Drug developer says U.S. FDA granted fast-track designation to its experimental drug, CTIM-76, for a hard-to-treat ovarian cancer that no longer responds to chemotherapy

** CTIM-76 targets platinum-resistant ovarian cancer, meaning the disease has stopped responding to standard platinum-based treatments, co says

** Says drug is being tested in an early-stage study in ovarian, endometrial and testicular cancers

** CTIM-76 is a bispecific antibody designed to help the immune system find and kill cancer cells, co says

** Adds interim results from the study are expected in June 2026

** Fast-track status is meant to speed development and review of treatments for serious diseases with unmet medical need

** As of last close, stock up ~80% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))